Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.

Published

Conference Paper

AIMS:Obesity is present in up to 45% of patients with heart failure (HF). Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor antagonist, facilitates weight loss in obese patients. The efficacy of liraglutide as a weight loss agent among patients with HF and reduced ejection fraction (HFrEF) and a recent acute HF hospitalization remains unknown. METHODS AND RESULTS:The Functional Impact of GLP-1 for Heart Failure Treatment study randomized 300 patients with HFrEF (ejection fraction ≤ 40%), both with and without diabetes and a recent HF hospitalization to liraglutide or placebo. The primary outcome for this post hoc analysis was the change in weight from baseline to last study visit. We conducted an 'on-treatment' analysis of patients with at least one follow-up visit on study drug (123 on liraglutide and 124 on placebo). The median age was 61 years, 21% were female, and 69% of patients had New York Heart Association functional Class III or IV symptoms. The median ejection fraction was 25% (25th, 75th percentile 19-32%). Liraglutide use was associated with a significant weight reduction [liraglutide -1.00 lbs vs. placebo 2.00 lbs; treatment difference -4.10 lbs; 95% confidence interval (CI) -7.94, -0.25; P = 0.0367; percentage treatment difference -2.07%, 95% CI -3.86, -0.28; P = 0.0237]. Similar results were seen after multivariable adjustments. Liraglutide also significantly reduced triglyceride levels (liraglutide 7.5 mg/dL vs. placebo 12.0 mg/dL; treatment difference -33.1 mg/dL; 95% CI -60.7, -5.6; P = 0.019). CONCLUSIONS:Liraglutide is an efficacious weight loss agent in patients with HFrEF. These findings will require further exploration in a well-powered cardiovascular outcomes trial.

Full Text

Duke Authors

Cited Authors

  • Sharma, A; Ambrosy, AP; DeVore, AD; Margulies, KB; McNulty, SE; Mentz, RJ; Hernandez, AF; Michael Felker, G; Cooper, LB; Lala, A; Vader, J; Groake, JD; Borlaug, BA; Velazquez, EJ

Published Date

  • December 2018

Published In

Volume / Issue

  • 5 / 6

Start / End Page

  • 1035 - 1043

PubMed ID

  • 30120812

Pubmed Central ID

  • 30120812

Electronic International Standard Serial Number (EISSN)

  • 2055-5822

International Standard Serial Number (ISSN)

  • 2055-5822

Digital Object Identifier (DOI)

  • 10.1002/ehf2.12334